Friday, October 21, 2011
Unigene Laboratories Inc., of Boonton, N.J., said all patients have completed the course of therapy in its Phase II study of an oral parathyroid hormone analogue in osteoporosis in postmenopausal women. Top-line data are anticipated by year-end. The drug is being developed in collaboration with London-based GlaxoSmithKline plc.
Outside of the US
Part of Thomson Reuters
Note: our contact information has changed
In the U.S. and Canada: +1-800-336-4474
Outside the U.S.: +44-203-684-1796
Hours: Monday - Friday, 8:00am - 6:00 pm EST
© 2017 Thomson Reuters. Reproduction, reposting content is strictly prohibited.